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Abbreviated according to chapter 68: “Parkinson’s disease: symptoms and age 
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Epidemiology of Parkinson’s Disease (PD)
Parkinson’s disease is one of the most frequent neurodegenerative diseases, which mainly 
affects the elderly. To estimate incidence and prevalence of PD, some problems need to 
be mentioned. No perfect ante mortem diagnostic test for PD exists and the most reliable 
diagnostic method is expert neurologic examination at regular time intervals. In autopsy 
studies, the diagnosis of PD before death has been found to be incorrect in about 24% 
of cases39. Essential tremor may account for 10% - 40% of the false-positive diagnoses of 
PD. In contrast PD may be misdiagnosed as depression, or in the very elderly, “normal” 
aging. Other neurodegenerative disorders, like progressive nuclear palsy (PSP) or multiple 
system atrophy (MSA) may not be distinguished easily from PD early in the course of 
the disease. Many “atypical” parkinsonian syndromes were only recognised in the past 
several decades and probably have been classified as PD in early reports. 
Incidence and prevalence of Parkinson’s disease
Several studies have been performed to estimate the frequency of PD. The overall incidence 
is estimated to be 20 / 100 000 per year, and raises to about 1% of persons over 50 
years of age32, 78 and even higher when older9. 
Prevalence of PD varies from 10 to 405 per 100 000 population. This variation may be 
due to differences in case-finding procedures, in diagnostic criteria, in accessibility of 
medical services and in the age distribution of populations. Most frequently prevalence is 
about 100 - 187 per 100 00059. As for incidence, prevalence rises almost exponentially 
after age 50. By the eighth decade, prevalence in Europe and North America is estimated 
to be between 1000 and 3000 per 100 000 persons88. This is confirmed by the Rotterdam 
Study: prevalence figures were 0.3% for those aged 55 to 64 years, 1.0% for those aged 
65 to 74 years, 3.1% for those aged 75 to 84 years and 4.3% for those aged 85 to 94 
years. Among women aged 95 to 99 years, prevalence was 5.0%16. In some studies an 
apparent decrease in late life is seen. This is probably due to ascertainment and diagnosis 
difficulties in this population, rather than an actual decline in disease frequency.  
Mortality 
In Hoehn and Yahr’s series mortality ratio in patients with primary parkinsonism 
was 2.9 times that expected in the age-matched population38. In a more recent study 
of parkinsonian patients the overall risk for death, adjusted for age and sex, was 2.0 
times that of persons without parkinsonism4. Since the introduction of more effective 
antiparkinsonian medication, especially levodopa, mortality has decreased in younger 
parkinsonian patients. However in older parkinsonian patients an increase during the last 










































decreased for persons younger than age 70, but increased for persons of 75 years and 
older49. This is confirmed by Morens et al67, who found that after age 60, PD-associated 
mortality rates appeared to increase logarithmically. This increase in mortality rate was 
not attributable to age alone. Increased age-related PD mortality was associated with 
both absolute age and duration of illness longer than 10 years. Between the ages of 70 
and 89 years, parkinsonian patients had a two- to three-fold increase in the risk of dying, 
corresponding to a mortality ratio of 2.567. In a study of Louis  et al54 risk of mortality was 
higher in parkinsonian patients (rate ratio = 2,7) after adjusting for baseline age, years of 
education, sex, ethnicity and smoking status. It was even higher when PD was combined 
with dementia (rate ratio = 4.9). In fact dementia is a significant predictor of death in PD57. 
A high base-line score of extrapyramidal signs was most associated with increased risk 
of mortality among the patients with PD.  After subanalysis of the different extrapyramidal 
signs, severe bradykinesia was the motor manifestation that most highly correlated with 
increased mortality54. The Sydney multicentre study found increased mortality risk among 
parkinsonian men, whereas this was not significantly different for women, compared to 
the general Australian population. Predictors of mortality, according to this study, are age 
at onset and progression rate. Several studies have shown that the effects of levodopa 
on mortality are apparent in the early years of the disease. In contrast, despite levodopa 
therapy, mortality is rising in a later stage of the disease12, 17. Data from the DATATOP cohort 
suggests that carefully selected patients with early PD without co-morbidity have normal life 
expectancy when adequately treated and frequently seen by consulting physicians1. This 
is confirmed by Tanner and Ben-Shlomo88. For persons with PD diagnosed before the age 
of 60, they found a relative survival similar to that of the general population, in contrast to 
people with an older age at diagnosis, who showed a lower relative survival88 . 
Pneumonia is the most common cause of death, probably due to immobility and increased 
risk of aspiration1. Death from cerebrovascular disease is increased as well35. Some studies 
have suggested a reduced risk of death from cancer in parkinsonian patients35, 42, but other 
studies did not confirm this91.
Regional and racial variation
Estimates of prevalence vary widely depending on geographical location. A Northwest 
to Southeast gradient is suggested49 and PD prevalence appears to be highest in Europe 
and North America, whereas rates in Japan, China and Africa are markedly lower. In 
the USA PD prevalence is much lower among blacks. Already in 1972, Kessler found a 
higher frequency of PD for whites compared with blacks43, 44. In a survey of PD in New 
York, age-adjusted prevalence rates were lower for blacks than for whites and Hispanics. 
Surprisingly however incidence rates were highest among black men, but these incidence 
rates were otherwise comparable across sex and ethnic groups. By ethnic group, the 














































cumulative incidence was higher for blacks than for whites and Hispanics, but more 
deaths occurred among incident black patients. These findings could result from a delay 
in diagnosis due to limited access to appropriate health services among these people60. 
Some studies however show similar rates for African-American, Asian-American and 
European-American subjects67. In a study among a cohort of American men of Japanese or 
Okinawan ancestry, epidemiological data are in general in accord with those from Europe 
and the United States. Incidence data are 5- to 10-fold higher at each age stratum than 
age-specific incidence figures from China. These findings most likely cannot be explained 
by methodological differences between Chinese and Western studies alone. However this 
possibility cannot be ruled out, as the Chinese data have not been verified yet by other 
studies67. Similar findings have been observed in a study in Mississippi, where black men 
and women have PD prevalence rates more like white men and women than black men and 
women in Nigeria79, 80. These data suggests that risk of developing PD is more a function 
of environmental factors than racial ones. So different distributions of PD causing factors 
across populations may contribute to geographic differences in epidemiological findings. 
These factors could be differences in exposure to causative and protective influences, but 
also genetic differences in susceptibility to disease. It could be that an environmental agent 
might only act in genetically susceptible people.   
Gender differences
Males tend to have a modestly increased age-adjusted PD prevalence. Male-to-female ratio 
range from 0.86 (in Japan) to 3.7 (Chinese studies). In a study in New York, age-adjusted 
prevalence was lower for women compared with men across all ethnic groups. However 
in another study, age-adjusted incidence did not differ between men and women in all 
ethnic groups60. This is confirmed by the Rotterdam Study in which no significant gender 
differences in prevalence were found16. 
Symptoms
Motor symptoms
The classic triad of symptoms of PD consists of tremor, rigidity and hypokinesia. Postural 
impairment has been called the fourth major symptom of PD. The disease is a slowly 
progressive disorder and signs and symptoms develop usually over several years. In the 
early stages of the disease the signs and symptoms may be vague and non-specific in such 
a way that a reliable diagnosis can not yet be made.
The typical parkinsonian tremor is a 3-6-Hz distal resting tremor. It consists of alternate 










































supinators of the wrists and arms during rest. This may result in a pill rolling movement 
of the hand. Often the typical parkinsonian rest-tremor starts on one side of the body. In 
most patients the signs will develop in due course on both sides, but asymmetry will usually 
persist throughout the disease. The legs or lower jaw may also be involved. The tremor 
tends to disappear with action. Resting tremor is found in 79% - 90% of patients with PD 
in clinical studies and in 76% - 100 % in autopsy-proven studies. Some patients have little 
or no resting tremor but a predominant action or postural tremor. Tremor at rest may also 
be induced by neuroleptic agents.
Rigidity can be present in all four limbs and in the trunk, but mainly affects the arms and 
is often of the cogwheel type. The increase in tone is fairly equal in flexors and extensors, 
but slightly more in flexors. It can be diagnosed in 89% - 99% of parkinsonian patients.
Bradykinesia means slowness of movements, whereas hypokinesia stands for poverty 
of movement. Hypokinetic features include facial hypomimia, reduced eye blinking, 
hypophonic speech and micrographia. There is difficulty in initiating movements, resulting 
in start hesitation. Rapid repetitive movements are impaired. Bradykinesia is present in 
77% to 98% of patients with PD, but it is not unique to PD. It can also occur as a result 
of other extrapyramidal disorders, such as PSP, MSA, CBD and normal aging. Symptoms 
can be gravitated by contralateral activation or concentration on mental or physical tasks. 
Each one of these features can be present for a long time, before others develop. Symptoms 
usually begin unilaterally or asymmetrical. Later they are bilateral or generalised.
Gait is impaired in patients with PD as well. The patients walk slowly with small shuffling 
steps. Parkinsonian patients move in a rigid manner and turn en bloc. Their posture is 
stooped, because of flexion of the shoulders, neck and trunk. In PD the center of gravity 
is shifted forward. Walking can be hampered by stutter steps, resulting in start- and turn-
hesitation, and sudden “freezing”. This phenomenon refers to the patient’s feet stuck to 
the ground while walking, rendering the patient unable to move with the lower body. It 
especially happens on turns and in elevators or doorways. Freezing and related phenomena 
are called motor blocks. It occurs in 32% of parkinsonian patients31. Retropulsion refers to 
the phenomenon that the standing patient if pushed backward, is only able to regain his 
balance slowly by small and slow steps or even fails to do so and falls. When walking, 
patients may have problems stopping and legs are preceded by the flexed trunk, resulting 
in frequent little short steps or propulsive gait. This pattern is characteristic of advanced PD. 
In the beginning of the disease symptoms are unilateral, affecting only one side. Patients 
appear to drag a leg when walking and arm swing is decreased at the affected side. In a 
later stage, when the opposite side is affected as well, steps are short and the feet barely 
clear the floor. Usually symptoms stay asymmetrical, in contrast to normal aging. In a later 
stage parkinsonian patients may experience problems of autonomic dysfunction such as 
constipation, incontinence, hypotension and impotence. If this occurs in an early stage of 
PD, the diagnosis should be questioned28 .














































Not only motor symptoms may occur. Another abnormality is for example an olfactory 
disorder. In PD there is an increase of the olfactory detection threshold70, which is probably 
due to the presence of Lewy bodies in the olfactory bulb and neuronal loss in the anterior 
olfactory nucleus14, 69. Other features include increased saliva production and increased 
sweating. 
None of the 3 major symptoms has enough sensitivity or specificity to diagnose PD. For this 
reason a scheme has been made for diagnostic classification: The UK Parkinson’s Disease 
Society Brain Bank clinical diagnostic criteria (see table 1: UK Parkinson’s Disease Society 
Brain Bank 1993)15.
Table 1
STEP 1  DIAGNOSIS OF PARKINSONIAN SYNDROME
* bradykinesia (slowness of initiation of voluntary movement with 
   progressive reduction in speed and amplitude of repetitive actions)
* and at least one of the following: 
- 4 - 6 Hz rest tremor
- rigidity
- postural instability not caused by primary visual, vestibular, cerebellar 
 or proprioceptive dysfunction  
STEP 2  EXCLUSION CRITERIA FOR PARKINSON’S DISEASE
* history of repeated strokes with stepwise progression of parkinsonian 
   features
* history of repeated head injury
* history of definite encephalitis
* oculogyric crises
* neuroleptic treatment at onset of symptoms
* more than one affected relative
* sustained remission
* strictly unilateral features after 3 years
* supranuclear gaze palsy
* cerebellar signs
* early severe autonomic involvement
* early severe dementia with disturbances of memory, language and praxis
* Babinski sign
* presence of cerebral tumour or communicating hydrocephalus on CT scan
* negative response to large doses of levodopa (if malabsorption excluded)
* MPTP exposure
STEP 3 SUPPORTIVE PROSPECTIVE POSITIVE CRITERIA FOR 
PARKINSON’S DISEASE
(three or more required for diagnosis of definite Parkinson’s disease)
* unilateral onset
* rest tremor present
* progressive disorder
* persistent asymmetry affecting side of onset most
* excellent response (70 - 100%) to levodopa
* severe levodopa-induced chorea
* levodopa response for 5 years or more











































In PD there are several other nonmotor clinical features, like dementia, depression and 
psychotic features.
Dementia 
In 20 to 40% of patients with PD cognitive impairment develops and the risk of dementia 
in non-demented PD patients is almost twice that of age-matched non-demented elderly 
controls. Prevalence however is estimated to be 10.9%61. Here it needs to be considered that 
PD patients with dementia have a shorter life expectancy. Dementia in PD is characterized 
by a severe dysexecutive syndrome without instrumental disorders like aphasia, apraxia 
or agnosia.  
In several studies the influence of age at onset on the presentation and course of PD has 
been demonstrated. Young onset patients have little cognitive impairment even after a 
disease duration of over 20 years73. Dementia mainly develops in patients with onset 
after 70 years. In this cohort of patients prevalence of dementia is more than twice that 
of younger patients61. Usually it develops after several years of disease duration. This in 
contrast to diffuse Lewy body disease, where cognitive deficits occur very early (less than 
2 years) or even precede motor symptoms19. Other risk factors for developing dementia 
in PD are lack of education and severe motor deficits (UPDRS motor scores above 24)56. 
Cognitive deficits however are usually less prominent than motor symptoms. 
Depression
Depression is estimated to occur in 30 - 60% of patients with PD at some point during 
the disease. It has been suggested that there is a natural tendency for chronic, disabling 
diseases to induce depression. However it appears that the prevalence of depression in 
patients with PD is higher than in other chronic disorders. Besides, the depression is unrelated 
to the severity of motor symptoms and depression can continue despite improvement in 
motor symptoms after L-dopa therapy. It is possible that depression precedes the motor 
symptoms of PD. There are some similarities between clinical and biochemical changes 
in PD and depression. Clinical similarities include akinesia and psychomotor retardation, 
while biochemical similarities include dysfunction in dopaminergic, noradrenergic and 
serotonergic systems. Reduced serotonergic function is associated with psychomotor 
retardation, reduced noradrenergic function with bradyphrenia and reduced dopaminergic 
function with extrapyramidal symptoms, cognitive slowing and more severe symptoms of 
depression51.















































Psychotic symptoms may either be a manifestation of the disease itself, or it may be the 
result of therapy with dopaminergic agents25. Psychosis may also occur as a reaction 
to the disease and functional impairment (“reactive psychosis”) as well, although this is 
probably a rare condition. About 30% of parkinsonian patients, treated with levodopa, 
have experienced psychotic symptoms and the lifetime prevalence may approach 50%. 
Visual hallucinations are most common and the images are usually fully formed human or 
animal figures. Usually insight is preserved2.
Pathology findings
The most prominent lesion in PD is the degeneration of neuromelanin-containing neurons 
in the pars compacta of the substantia nigra, which at post-mortem inspection turns visibly 
pale. Also selected aminergic brain-stem nuclei (catecholaminergic and serotoninergic), 
the cholinergic nucleus basalis of Meynert, hypothalamic neurons, small cortical neurons 
(particularly in the cingulate gyrus and entorhinal cortex), olfactory bulb, sympathetic 
ganglia and parasympathetic neurons may be involved in this progressive degenerative 
process. 
Not all dopaminergic neurons are equally susceptible. Within the substantia nigra pars 
compacta, neuronal loss appears to be greatest in the ventrolateral part, followed by the 
medial part and the dorsal part24. This has been confirmed by Damier and coworkers13. 
It results in a regional loss of striatal dopamine50. The nigrostriatal dopaminergic neurons 
which project to the putamen are more affected than those which project to the caudate 
nucleus and nucleus accumbens. The latter one is believed to be responsible for akinesia 
and rigidity. This pattern of cell loss seems to be rather unique to Parkinson’s disease and 
is different of the pattern seen in normal aging. Neuronal loss of the medial nigral cells, 
with enhanced involvement of projections to the caudate nucleus, could result in more 
cognitive symptoms. Another possible clinical-pathological correlation may be based on 
degenerative changes of the olfactory bulb, causing anosmia. Autonomic dysfunction may 
be the result of lesions in the sympathetic and parasympathetic ganglia or degeneration in 
the intermediolateral columns of the spinal cord75. Some believe that dementia in PD may 
be the result of cell loss in the nucleus basalis of Meynert77.
The surviving, but dying catecholaminergic neurons may contain Lewy bodies, an important 
pathological feature. Lewy bodies are spherical, eosinophylic cytoplasmic inclusions with 
a dense core and peripheral halos, found in pigmented cells. In PD the most important 
anatomical sites where these bodies are located are the substantia nigra and locus 










































disorders, like Alzheimer’s disease (AD). AD however is associated with cortical Lewy 
bodies, particularly in frontal, temporal, anterior cingulate and insular regions, whereas 
PD is associated with subcortical Lewy bodies, mainly in the substantia nigra. Lewy bodies 
are also seen as an incidental finding in about 10% of people older than 60 years. Gibb 
and Lees30 discovered that the age-specific prevalence of Lewy bodies in the brains of 
persons without clinical PD increased from 3.8 to 12.8% between the sixth and ninth 
decade of life. It has been suggested that the presence of incidental Lewy-bodies constitutes 
actually a presymptomatic stage of PD30. McKeits however suggests a relationship between 
this “incidental” pathology and dementia with Lewy bodies62.
The mechanisms of cell death in PD are still unknown. Several factors have been mentioned 
to play a role in neuronal degeneration in PD, like mitochondrial dysfunction, oxidative 
stress and excitotoxity and free radical production. It is believed that the neuronal death in 
the pars compacta of the substantia nigra is apoptotic6, 7, but this has not been universally 
accepted yet and necrosis has been suggested as well.
Other movement disorders in the elderly
Aging is a unequivocal risk factor for PD87. It is also a major risk factor for several other 
movement disorders and neurodegenerative diseases.
There are many causes of movement or gait disorders in the elderly, of which some can 
easily be mistaken for PD. The many characteristics and patterns of gait disorders may look 
difficult and require special expertise, but simple observation of the patient and its gait may 
yield valuable information. The history from patients may reveal a stepwise progression, 
suggesting vascular disease. Pain with walking usually excludes a neurodegenerative 
cause of the gait disorder. Magnetic Resonance Imaging (MRI) may be used for screening 
for hydrocephalus or multiple infarcts. Positron emission tomography (PET) scans of the 
brain may for example help for diagnosing PD, MSA or PSP. Gait disorders in the elderly, 
irrespective their underlying pathology, contribute to the risk of falling and fractures89. The 
higher risk of falling limits the elderly in their mobility and independence, also because of 
the fear of falling itself. Imms and Edholm surveyed in 1981 a group of older people (mean 
age, 78 years) and found that half of them limited their activity because of their concerns 
about mobility40. 
Many signs of gait disorders, slowing down and stiffening up, are accepted as being part 
of aging.  However most of these signs may be signals of an underlying disease. Critchley 
already warned in 1931 that “an abnormal gait in the aged is frequently the result of 
disease outside the nervous system” (Critchley, 1931). In many cases gait disorders are 
of orthopedic (osteoarthrosis, osteomalacia, unsuspected fractures), endocrinological 














































(hypothyroidism), psychological (depressive state, fear of falling) or general (general 
muscle weakness) origin11. Circulatory or respiratory systems may play a role as well 
in determining gait velocity because of the need to minimize energy expenditure23. The 
incidence of subtle extrapyramidal signs on neurological examination of elderly persons 
with no known neurologic or psychiatric disorder is high. Bennett et al4 showed that 35% 
of people over 65 years old had these subtle changes, while around 3% in similarly aged 
persons had PD. In a community study in North Carolina, 15% of adults over 60 years of 
age had some degree of difficulty with ambulation18. In Western Europe 20-25% of people 
aged 80 or older, use mechanical aids for walking55. A review of the variety of conditions, 
which can cause gait disorders or may be confused with PD, will be given here.
Essential tremor (ET)
One of the commonest causes of misdiagnosis of PD is essential tremor (also known as 
senile tremor, which is a misnomer). It is inherited as an autosomal dominant disorder 
with incomplete penetrance. A familial incidence is common in about one-third to one-
half of cases. In the elderly however it is often sporadic32. The incidence of essential 
tremor increases with climbing age. Considering prevalence Rautakorpi’s study76 reported 
a prevalence of 12.5% in his population. In a study of a population aged 65 and older, 
Louis et al53 found a prevalence of 4%. A higher prevalence of 23% in a population of 
people older than 70 years has been observed by Elble22. 
Essential tremor is an action tremor with a frequency of 8- to 12-Hz (the resttremor in 
PD is 4- to 6-Hz). It may sometimes be present at rest as well, but generally increases 
with activity. The amplitude increases with age. According to Marttila and Rinne essential 
tremor accounted for 26% of cases of presumed PD58. This misdiagnosing can occur 
because of many reasons. Both conditions frequently occur in the elderly. Parkinsonian 
patients sometimes suffer from a postural action tremor of the hands, as seen in ET. Patients 
with ET may have some bradykinesia and rigidity, which could be normal in the elderly. 
Besides, some hallmarks of PD, like asymmetric manifestation and a resting component of 
the tremor, can also be found in cases of ET. 
However, there are also some striking differences between these two disorders. Essential 
tremor frequently involves the head in contrast to tremor in PD. Conversely, a resttremor of 
the leg or slow vertical jaw tremor is often seen in PD, but rarely in essential tremor. Also, 
hypokinesia may be present in PD, but not in ET. 
Vascular parkinsonism
This results from multiple small cerebral infarcts, especially in the basal ganglia secondary 
to hypertensive cerebrovascular disease. Some patients with vascular parkinsonism 










































hypertension leads to fibrinoid necrosis and occlusion of arterioles supplying the basal 
ganglia. An akinetic rigid syndrome with urinary incontinence, dysarthria, abulia and 
dementia may occur. The extrapyramidal signs may coexist with pyramidal dysfunction like 
weakness, hyperreflexia, spasticity, pseudobulbar palsy, emotional lability and Babinski 
signs. These pyramidal signs may be important in differentiating this disorder from PD. 
The patient is slow and walks wide-based (unlike in PD) with short, shuffling, somewhat 
irregular footsteps. Postural stability may be impaired. As in PD freezing and start hesitation 
may occur. 
However the upper body may show little or no parkinsonian features, thus no facial 
hypomimia may occur. Another term used for this disorder is lower body parkinsonism. 
Another striking difference with PD is usually the absence of tremor and no fatigue or 
decrement of rapid alternating movements. In vascular parkinsonism symptoms are 
symmetric in contrast to PD. However, if signs and symptoms are not clear cut, the 
differential diagnosis may be difficult.
Computerised tomography shows multiple infarcts but sometimes misses small ones. 
Magnetic resonance imaging demonstrates infarctions in the deep gray matter structures 
and ischemic changes in periventricular white matter. According to Sudarsky, vascular 
parkinsonism accounts for 15 - 16% of the gait disorders among elderly patients83, 84.
Multiple system atrophy (MSA)
MSA refers to a sporadic, gradually progressive, idiopathic neurodegenerative process 
of adult onset characterized by varying proportions of cerebellar dysfunction, autonomic 
failure, pyramidal signs and parkinsonism, that is poorly responsive to L-dopa therapy. Cell 
loss and gliosis (without Lewy bodies) are not only present in substantia nigra, but also 
in multiple other structures, like striatum, olives, pons, cerebellum, intermediolateral cell 
columns and Onuf’s nucleus in the spinal cord. Most commonly MSA begins in the early 
50s, progresses more rapidly than PD and has a reduced life expectancy (median survival 
= 9.3 years), this in contrast to PD (see above). 
Parkinsonism occurs in 90% of patients with multiple system atrophy and is the dominant 
motor disorder is 80% of patients. In contrast to PD, the parkinsonism in MSA is usually 
bilateral. Unlike PD, tremor is often not the classical rest tremor, but an action tremor. 
Cerebellar dysfunction and pyramidal signs both occur in about half of patients71, 90. 
Cerebellar dysfunction as the dominant symptom occurs in about 20% of patients74. 
Autonomic failure appears in almost all patients with MSA. In PD patients it may occur 
as well, mostly in a late stage of disease, whereas in MSA it usually occurs earlier and 
more severe. Indeed, in MSA, autonomic failure may precede the motor symptoms by 
months or even years. Frequently, the first symptom is impotence in men and incontinence 
in both men and women (PD usually causes just frequency increase and urgency due to 














































hyperreflexia of the detrusor). Postural hypotension is another common feature in MSA, 
which may appear in PD as well, though less severe. Inspiratory stridor is present in about 
30% of patients with MSA. When combined with parkinsonism it is highly suggestive of 
the diagnosis MSA72. Other signs of autonomic failure are thermoregulation disturbances, 
gastro-intestinal problems and phenomena of Raynaud. 
The response to levodopa of patients with MSA is usually absent or poor. However, in 
about 30% of patients an initial response has been reported, usually temporary. Levodopa 
induced dyskinesias are usually absent in MSA, so high doses of levodopa can be 
administered.
Differentiating MSA from PD may be very difficult, especially in an early stage of disease. 
There are some red flags suggesting non-idiopathic parkinsonism, like: 
•	 Poor or no response to levodopa therapy
•	 Cerebellar, pyramidal or autonomic signs
•	 Symmetric start of symptoms
•	 Absence of classic rest tremor
•	 Early instability or falls
•	 Rapid clinical progression71, 74, 90. 
Some diagnostic tests may include external urethral (or anal) sphincter EMG, standard tests 
of cardiovascular autonomic function and imaging of the brain. Computed tomography 
or magnetic resonance imaging sometimes shows cerebellar or brainstem atrophy. 
Fluorodesoxyglucose positron emission tomography (PET) scanning may be useful as 
well20, 86.
Progressive supranuclear palsy (PSP)
PSP, or Steele-Richardson-Olszewski syndrome, is an idiopathic degenerative disease, not 
uncommon in the elderly, which mimics PD. It occurs at a rate of 0.3 per 100.000 per 
year34 and its prevalence is 1.46 per 100.000. Pathologic investigation shows cell loss 
and neurofibrillary tangles, mainly in the brainstem, globus pallidus, nucleus subthalamicus 
and nucleus dentatus. 
The clinical picture includes the tetrad of supranuclear gaze paralysis, axial rigidity, 
dementia and pseudobulbar palsy. It is associated with bradykinesia, severe postural 
disorder and frequent falls. Supranuclear gaze paralysis affects vertical gaze more than 
horizontal. Voluntary downgaze is slow and usually incomplete, but when the oculocephalic 
reflex is performed, full down gaze is obtained. Pseudobulbar palsy is characterised by 
dysphagia and dysarthria. Dementia is progressive and consists of slowing of cognition, 
memory deficits and personality changes suggestive of frontal lobe dysfunction52. PSP may 
be distinguished from PD by the absence of rest tremor, the extended neck posture, rigidity 










































based gait with ataxia. In contrast to PD patients they do not turn en bloc, but pivot. During 
pivoting they also tend to fall backwards.
Cortico-basal degeneration (CBD)
This disorder presents with a unique pattern of progressive impairment. It appears in mid- 
to late adult life, usually beginning after age 60. The duration of the illness until death is 
about 6 to 8 years. Pathologic and histologic evaluation reveal frontoparietal atrophy and 
neuronal loss, gliosis and swelling of the cell body with resistance to staining methods 
(achromasia)45. 
Prototypic findings are combined parkinsonian signs, other movement disorders and 
higher cortical dysfunction, with marked asymmetry of involvement. The most common 
extrapyramidal sign is rigidity, followed by bradykinesia. Sometimes tremor is present 
as well, but does not resemble the parkinsonian tremor. Tremor in CBD is more rapid 
(6-8Hz), is mainly during action, with varying amplitude. Other movement disorders 
include myoclonus and dystonia. Higher cortical dysfunction includes dyspraxia, involving 
the limbs, ocular and orofacial muscles, cortical sensory loss, dementia (which usually 
occurs late in disease) and aphasia. A striking feature of CBD is the “alien hand/limb” 
phenomenon81.
Normal pressure hydrocephalus (NPH)
This disorder is often idiopathic, but has also been associated with many neurological 
diseases. The classic triad of symptoms includes frontal dementia, urinary incontinence and 
gait disorder with unsteadiness. It is associated with enlargement of the cerebral ventricles 
on CT or MRI and a CSF pressure of 180 mm H2O or less. A dynamic test is necessary to 
confirm the diagnosis of true (opposed to ex vacuo) hydrocephalus5. The removal of 50 
ml of cerebrospinal fluid may improve the symptoms of gait disorder85. Mental dysfunction 
improves less than gait after a shunt. The patient walks wide-based with small steps, feet 
glued to the floor, marked imbalance and difficulty initiating walking. Postural instability 
with frequent falling may occur. Clinical signs may include hyperreflexia, extensor plantar 
responses and extrapyramidal signs, including hypokinesia and freezing during walking. 
Diagnosing NPH may be difficult since the three cardinal symptoms are common in the 
elderly. Besides gait disorder may precede other symptoms for several years and can 
be the only symptom for a long period. NPH is a common cause of gait disorders in the 
elderly, while in dementia it accounts for only 0 - 5% of persons with dementia26. It should 
account for 4 - 6.7% of the gait disorders in the elderly84, 85.














































Metabolic and endocrine disorders
Some of these disorders may produce akinetic-rigid syndromes. Hypothyroidism may 
cause parkinsonism with motor slowing. Hypoparathyroidism, resulting in calcifications of 
the basal ganglia, may produce a clinical syndrome consisting of parkinsonism, chorea, 
cerebellar dysfunction or a mixed extrapyramidal-pyramidal syndrome, resembling the 
lacunar state48. Metabolic and toxic disorders causes gait disorders in 2,5 % of the 
elderly83, 84.
Drug-induced parkinsonism
Many drugs commonly prescribed in the geriatric practice can affect gait. It can be caused 
by: 
•	 drugs that deplete presynaptic dopamine stores, like reserpine or tetrabenazine
•	 neuroleptic drugs, like phenothiazines (chlorpromazine), butyrophenones 
(haloperidol), thioxanthines (flupenthixol) and substituted benzamides (sulpiride) 
•	 metoclopramide for gastrointestinal symptoms or migraine
•	 the atypical calcium blocking drug cinnarizine and flunarizine for vestibular 
disorders or hypertension
•	 others, like fluoxetine and rarely valproate
Drug-induced parkinsonism results in bradykinesia and rigidity with facial amimia, 
dysarthria and diminished or disappeared arm swing. Tremor is less common, but can be 
identical to the classic rest tremor of PD. Moreover symptoms of drug-induced parkinsonism 
usually are, just like in PD, asymmetrical. Drug-induced parkinsonism often resolves quickly 
within weeks after stopping those drugs. Sometimes this will take months, especially after 
depot neuroleptic medications.
Subclassification of PD
The variance in expression of the clinical syndrome of PD is large and suggests the existence 
of subtypes with distinct clinical patterns, especially concerning  the age of symptom onset, 
rate of disease progression and clinical manifestations. Probably this clinical heterogeneity 
reflects a broad spectrum of manifestations of one pathological disorder: the loss of 
pigmented neurons in the substantia nigra pars compacta and the presence of Lewy bodies 
(intracytoplasmic inclusions). Several studies have tried to define clinical subgroups on the 
basis of distinguishing features, like family history of PD, variable progression and age of 










































Young-onset versus old -onset of PD
Friedman has compared clinical expression of patients with onset age of symptoms above 
70 years with patients with onset age below 45 years27. In this study there were some striking 
differences between these groups. The DATATOP (deprenyl and tocopherol antioxidative 
therapy of parkinsonism)- study has investigated the variability in clinical expression by 
comparing several factors, like early versus late onset of disease, benign versus malign 
status, H/Y stage I versus H/Y stage II and tremor versus postural instability and gait 
disorder (PIGD) type41. This study suggests that there are probably 2 different subtypes 
of PD: early-onset and late-onset of disease. Patients with early onset of PD progress at a 
slower rate, which has been confirmed by others33. Patients with young-onset of disease 
are more sensitive to levodopa and to levodopa-induced dyskinesias, and dyskinesias 
seem to appear earlier in those patients. Not only will they develop focal dystonia early in 
the course of illness, but also end-of-dose phenomenon is more often observed in patients 
with young-onset of disease29, 73. Similarly, motor fluctuations, such as the wearing-off 
effect, tend to occur earlier in young-onset patients47. Initial symptom in this group is usually 
tremor. This is in contrast to Friedmans results27 who found that young-onset patients usually 
start with paraesthesia and have bradykinesia as dominant symptom. They tend to perform 
better on neuropsychological tests, but this may be explained by their younger age. 
Patients with late-onset of disease have a more aggressive form of PD with faster progression 
and greater motor disability. They have as initial symptoms bradykinesia, postural 
instability, rigidity and less often tremor, according to the DATATOP-study. This study also 
suggests that motor deterioration in PD does not necessarily parallel cognitive decline and 
it is postulated that cognitive impairment in PD results mainly from a nondopaminergic 
deficit. According to Friedman27 old-onset patients with PD more often have tremor as 
both presenting and dominant symptom. Old-onset parkinsonian patients more frequently 
develop psychotic complications and less frequent dyskinesia as complication of levodopa 
treatment than young-onset ones. Friedman found a striking difference in symptomatology 
of psychotic complications. Whereas old-onset patients used to have simple, mostly visual 
hallucinations with preserved insight, young-onset ones tend to develop paranoid behaviour 
without preserved insight. The number of young-onset patients with psychotic complications 
however was very low in this study. There was no striking difference in overall functioning 
based on activities of daily living (ADL) between those two groups. According to Friedman27, 
the lesion in young-onset PD concerns predominantly the dopaminergic system. This 
monosystemic lesion may explain the greater susceptibility to dyskinesia (and the fact that 
bradykinesia is the dominant symptom of this disease). Lower susceptibility to dyskinesia 
in old-onset parkinsonian patients could be the result of age-related decline in the number 
of dopaminergic receptors in striatum. In contrast old-onset patients are more susceptible 
to developing psychotic complications, probably due to more widespread lesions of the 














































central nervous system resulting from ageing. Older people are in general more likely to 
develop psychotic reactions to various external stimuli, e.g. infections, intoxications, etc 
46. Age-related brain atrophy involving also other neurotransmitter systems is probably 
the reason for the different symptoms in PD between old-onset and young-onset patients27. 
Some studies have observed a higher frequency of a first-degree relative with PD in young-
onset patients3, 82, although other studies found no difference in the number of affected 
relatives among young- and old-onset cases29, 73. Others have noted an increased exposure 
to farming and rural living in patients with young-onset of disease. Despite the differences 
in clinical manifestation, the cellular morphology and frequency of Lewy bodies in the 
substantia nigra are identical in young-and old-onset cases29.
Other subtypes of PD
Several other studies have investigated the existence of possible subgroups of PD, including 
young onset, tremor dominant, postural instability/gait disorder predominant, benign and 
malignant forms. Comparing tremor-dominant versus postural instability/gait disorder-
dominant PD (PIGD), greater motor disability has been found in the latter group. Patients 
with tremor as dominant symptom usually did not only have more severe tremor at rest, 
but also more severe action- and postural tremor. PIGD patients had, in addition to their 
greater postural and gait difficulties, more severe bradykinesia and rigidity41. 
Some authors have divided patients into benign or malignant groups based on duration 
of symptoms and stage of disease. Patients were arbitrarily considered to have a benign 
form of PD if they were Hoehn and Yahr stage 2 or less, combined with parkinsonian 
symptoms for 4 years or less. In contrast, patients with malignant PD were those with early 
postural imbalance, while disease duration is less than 1 year. Patients with a benign form 
of PD usually were younger at onset of disease and had tremor as dominant symptom. 
Indeed, benign tremulous parkinsonism is considered to be a well-recognized subgroup 
of patients with a relatively nonprogressive, long-term course of disease. The benign 
group had an earlier onset than the malignant one and the latter one performed slightly 
worse on the Mini Mental State Examination, although this difference was not statistically 
significant after adjusting for age. To distinguish the benign form from the malignant one, 
other factors may be important as well, like response to medication, genetic factors and 
cognitive impairment82. Hely et al suggest that patients with a benign form of PD have mild 
dyskinesia, if present, and that none of these patients had dementia or hallucinations. All 
of them are responsive to drugs37.
Graham and Sagar have investigated the heterogeneity in PD, using a data-driven 
approach36. They suggested the existence of three distinct subtypes: 
•	 a motor only subtype, without intellectual impairment
•	 a motor and cognitive subtype










































The latter group is characterized by an older age of disease onset than the other subtypes, 
rapidly progressive motor and cognitive disability and more orthostasis. Because of the 
rapid progression patients belonging to this subtype have a shorter life expectancy than 
the other groups. This is confirmed by Louis et al54, who found that mortality increases with 
climbing of the years, the development of dementia and the severity of motor disability.
Gender may be associated with a different progression of PD. According to the Sydney 
multicentre study of Parkinson’s Disease, dyskinesia develops earlier in women during the 
first 10 years of disease. After 10 years there is no significant difference in the prevalence 
of dyskinesia, but women tend to have a higher score in Hoehn and Yahr stage37.
Brain metabolism in aging and Parkinson’s Disease
During development and aging, the brain will change anatomically and physiologically to 
support the behaviour of normal adults. Chugani et al8 have investigated the maturation 
of the brain during the first years of life by using positron emission tomography (PET) and 
2-deoxy-[18F]fluoro-D-glucose (FDG). They discovered that in the first 4 weeks of life (the 
neonatal period), the most important region of metabolic activity is the primary sensorimotor 
area, while high activity was also found in the thalamus, brainstem and cerebellar vermis. 
The second postnatal month a small increase in metabolism in calcarine and temporal 
cortices can be seen. Approximately 3 months after birth, considerable rises in metabolic 
activity in the anterior parietal, temporal and calcarine cortices as well as in basal ganglia 
and cerebellar cortex were found. By 1 year, the metabolic pattern resembled that in 
adults, but absolute values were lower than adult ones. Adult rates were reached by 2 
years of age. Metabolic rates continued to rise until 3 - 4 years, so values exceeded those 
of adults by a factor of approximately 2. These high values were maintained until age 8 
- 9. At this age, they begin to decline and by the end of the second decade adult values 
are reached. The highest increases in metabolic activity were observed in the cerebral 
cortices8.
Aging is associated with the degeneration of specific neural systems. Normal aging is 
predominantly characterized by metabolic changes in the prefrontal cortex. By using 
FDG-PET scans metabolism of these systems can be investigated. Moeller and coworkers65 
have tried to explore the metabolic topography of aging. They found various topographic 
profiles. One was characterized by relative frontal hypometabolism associated with 
covariate metabolic increases in the parietooccipital association areas, basal ganglia, 
mid-brain and cerebellum. Another one revealed relative basal ganglia hypermetabolism 
associated with covariate decreases in frontal premotor cortex65. Mielke et al also found a 
decline of regional cerebral glucose metabolism in frontal areas63. 














































Although the most important lesion in PD is located in the substantia nigra and its 
dopaminergic projections, lesions of the presynaptic nigrostriatal dopamine system 
result in widespread abnormalities in regional brain metabolism. To define the metabolic 
topography of parkinsonism the same strategy as above has been used. According to 
the results of Eidelberg and coworkers21 the metabolic profile of PD is characterized by 
increased activity in the lentiform nucleus, thalamus, pons and cerebellum whereas activity 
was decreased in the lateral frontal, paracentral and parietal association areas. Increase 
in activity in the lentiform nucleus and thalamus in PD is consistent with experimental 
animal studies64, 68. Increased metabolism in the ventral thalamus has been confirmed by 
others10, 68. The subject scores for the metabolic profile in PD correlated with the individual 
Hoehn and Yahr score and with rigidity and bradykinesia ratings, but not with tremor21, 
68. The reproducibility of this unique pattern of regional metabolic covariation in patients 
with PD has been assessed by Moeller et al66, 68. This topography appears to be highly 
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